UDM 002555

Drug Profile

UDM 002555

Alternative Names: UDM-002555

Latest Information Update: 29 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antithrombins; Small molecules
  • Mechanism of Action PAR-4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Arterial thrombosis

Most Recent Events

  • 27 Aug 2016 Preclinical trials in Arterial thrombosis in USA (PO)
  • 27 Aug 2016 Data from preclinical studies in arterial thrombosis presented at the ESC Congress 2016: Annual Congress of the European Society of Cardiology (ESC-Card - 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top